Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials

Novolog Mix 70/30

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved November 2001

Specific Treatments:


Therapeutic Areas

General Information

Novolog Mix is an insulin analog premix containing 30% rapid-acting insulin aspart and 70% that has been modified into a long-acting formulation. It has been approved in a subcutaneous injection formulation, for the control of hyperglycemia. Hyperglycemia is an abnormally increased content of sugar in the blood.

Diabetes is a chronic disease that requires a combination of professional medical care and self-management through strict attention to diet, self-medication, and frequent monitoring one's blood sugar level.

Clinical Results

Approval of NovoLog Mix 70/30 is based on results from clinical trials evaluating glycaemic control in subjects with type 1 and 2 diabetes.

Side Effects

Adverse events associated with the use of human insulin therapy include (but are not limited to) the following:

  • Injection site reaction
  • Lipodystrophy
  • Pruritus
  • Rash
  • Hypoglycemia

Mechanism of Action

NovoLog Mix 70/30 regulates glucose metabolism. Insulins, including Novolog Mix, bind to insulin receptors on muscle and fat cells. They lower blood glucose by facilitating the cellular uptake of glucose, while simultaneously inhibiting the output of glucose from the liver.

Additional Information

For additional information on Novolog Mix 70/30, please visit Novo Nordisk.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation